← Eichor
Condition: Mismatch Repair Deficiency Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Mismatch Repair Deficiency

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07270666DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With H
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05770102PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsa
Phase 3 · 1 location(s) · Centre Hospitalier Universitaire Dijon · NCT06762405AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Phase 1 · 22 location(s) · Amgen · NCT07403721Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
Phase N/A · 5 location(s) · San Raffaele University · NCT06708429PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT05236972Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT03926338NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer
Phase 2 · 6 location(s) · University College, London · NCT05197322Small Bowel Capsule Endoscopy in Lynch Syndrome
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07472686Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06903858A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06686576SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)
Phase 2 · 3 location(s) · Queensland Centre for Gynaecological Cancer · NCT06278857SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer
Phase N/A · 1 location(s) · Xijing Hospital · NCT06613165Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
Phase 2 · 9 location(s) · Royal Marsden NHS Foundation Trust · NCT06250036Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
Phase 2 · 8 location(s) · Yu jiren · NCT05729646Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT04636008A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Phase 1/Phase 2 · 22 location(s) · Nimbus Wadjet, Inc. · NCT06898450Tislelizumab in People With Colorectal Cancer
Phase 2 · 3 location(s) · Memorial Sloan Kettering Cancer Center · NCT06529523Familial Investigations of Childhood Cancer Predisposition
Phase N/A · 1 location(s) · St. Jude Children's Research Hospital · NCT03050268TT-702 in Patients With Advanced Solid Tumours.
Phase 1/Phase 2 · 3 location(s) · Cancer Research UK · NCT05272709Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Phase 2 · 30 location(s) · BeiGene · NCT03736889Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or
Phase 2 · 5 location(s) · Emory University · NCT07140679A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
Phase 1 · 1 location(s) · Jemincare · NCT07208136A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer
Phase 1/Phase 2 · 22 location(s) · GlaxoSmithKline · NCT07213609Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
Phase 2 · 17 location(s) · Cambridge University Hospitals NHS Foundation Trust · NCT05093231Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/Phase 2 · 7 location(s) · Neonc Technologies, Inc. · NCT06047379177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
EARLY_Phase 1 · 5 location(s) · Radiopharm Theranostics, Ltd · NCT06305962
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.